Table 1 Patient clinical and pathologic Characteristics

Sex

0.60

Male

72

69.2

77

74

78

75

Female

32

30.8

27

26

26

25

Age, years

65.2

11.7

65.5

9.8

66.8

9.4

0.59

BMI, kg/m²

22.6

3.5

22.3

3.1

22.1

3.1

0.55

Tumor size, cm

3.9

2.3

4.1

2.5

4.3

2.7

0.79

Histology

0.48

Adenocarcinoma

95

91.3

98

94.2

99

95.2

Signet-ring cell carcinoma

5

4.8

6

5.8

4

3.8

Neuroendocrine tumor

1

1.0

0

0.0

1

1.0

Low adhesion carcinoma

3

2.9

0

0.0

0

0.0

Differentiated degree

0.16

Low

81

77.9

72

69.2

69

66.3

Medium

21

20.2

29

27.9

32

30.8

High

2

1.9

3

2.9

3

2.9

Tumor distribution

0.88

Upper third

13

12.5

9

8.7

11

10.6

Middle third

29

27.9

32

30.8

33

31.7

Lower third

62

59.6

63

60.6

60

57.7

Pathologic T stage

0.66

<T2

36

34.6

29

27.9

33

31.7

T2-4a

68

65.4

75

72.1

71

68.3

Pathologic N stage

0.97

N0

52

50.0

54

51.9

52

50.0

N1

14

13.5

9

8.7

11

10.6

N2

15

14.4

12

11.5

16

15.4

N3

23

22.1

29

27.9

25

24.0

Pathologic TNM stage

0.97

<IB

31

29.8

26

25.0

28

26.9

IB

9

8.7

11

10.6

9

8.7

IIA

12

11.5

12

11.5

12

11.5

IIB

13

12.5

16

15.4

17

16.3

IIIA

12

11.5

12

11.5

12

11.5

IIIB

21

20.2

26

25.0

24

23.1

IIIC

6

5.8

1

1.0

2

1.9

Clinical T stage

0.80

<T2

36

34.6

34

32.7

33

30.5

T2-4a

68

64.4

70

67.3

71

64.7

Clinical N stage

0.51

N0

50

48.1

55

52.9

54

49.9

N1

17

16.3

20

19.2

19

17.6

N2

17

16.3

16

15.4

18

16.6

N3

20

19.2

13

12.5

13

12.0

Clinical TNM stage

0.91

<IIA

39

37.5

40

38.5

39

36.1

IIA

4

3.8

3

2.9

4

3.7

IIB

11

10.6

16

15.4

15

13.9

III

50

48.1

45

43.3

46

42.5